VativoRx, LLC

08/10/2026

FDA expanded Skyrizi® (risankizumab) for kids 6+ with moderate-to-severe plaque psoriasis and psoriatic arthritis, including a new 55mg formulation for smaller patients. An established adult biologic now accessible to pediatric patients.

https://vativorx.com/pharmacy-bulletin-08-10-2026/

On June 26, 2026, the US Food and Drug Administration (FDA) approved a new indication and formulation of AbbVie’s Skyrizi® (risankizumab-rzaa). Now approved for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or...

08/07/2026

FDA approved Tregzi™ an engineered cell therapy for blood cancer patients undergoing stem cell transplants. In trials, it cut chronic GVHD rates from 44% to 13% and improved cGVHD-free survival to 78% vs. 38%. One-time treatment, $428K WAC.

https://vativorx.com/pharmacy-bulletin-08-07-2026/

On June 30, 2026, the US Food and Drug Administration (FDA) approved Tregzi™ [allogeneic regulatory T cell immunotherapy with hematopoietic stem and progenitor cells (HSPCs) and T cells-vldq – Orca Bio] for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative ...

08/06/2026

FDA-approved Lumvoa™ (veligrotug) for thyroid eye disease, active or chronic. A new competitor to Tepezza® in the IGF-1R space, with data showing proptosis improvement as early as 3 weeks. Launched immediately.

https://vativorx.com/pharmacy-bulletin-08-06-2026/

On June 26, 2026, the US Food and Drug Administration (FDA) approved Viridian Therapeutics’ Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED), regardless of disease activity or duration. Lumvoa is a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R).

08/04/2026

FDA expanded Hympavzi® for hemophilia A & B, now covering kids 6+ and patients with inhibitors. In a trial, it cut the annualized bleeding rate by 93% vs. on-demand IV therapy. Once-weekly SC prophylaxis just got a lot more accessible.

https://vativorx.com/pharmacy-bulletin-08-04-2026/

On June 8, 2026, the US Food and Drug Administration (FDA) approved Pfizer’s Hympavzi® (marstacimab-hncq) for expanded use as a once-weekly subcutaneous (SC) prophylactic treatment to prevent or reduce bleeding episodes in adults and pediatric patients aged six years and older with hemophilia A o...

07/31/2026

Today is the effective date for pharma tariffs on 17 large manufacturers. The picture is clearer than it was in April, and one piece of it changed significantly last week.

New edition of The Rebate Report covers where things actually stand as of today. 👇

📋 https://www.linkedin.com/pulse/pharma-tariff-deadline-arrived-heres-where-things-actually-zkpqe

In April, we covered the Section 232 pharmaceutical tariff proclamation as a developing situation, legally grounded, but still taking shape through manufacturer negotiations. Today, July 31st, is the first effective date.

07/21/2026

FDA expanded Afrezza® inhaled insulin to kids and teens aged 6+ with diabetes. First inhaled mealtime insulin option for pediatric patients, a needle-free alternative for the 350,000+ children living with diabetes in the US.

https://vativorx.com/pharmacy-bulletin-07-21-2026/

n May 29, 2026, the US Food and Drug Administration (FDA) expanded MannKind Corporation’s Afrezza® (insulin human) inhalation powder for the treatment of diabetes mellitus type 1 and type 2 in children and adolescents aged six years and older.

07/20/2026

Your PBM has your pharmacy rebates covered. But what about the manufacturer rebates owed on the specialty drugs billed under your medical benefit? For many self-funded plans, that's a blind spot and a recoverable opportunity. We're bringing that conversation to the HCAA TPA Summit in Nashville.

Read our quick take: https://vativorx.com/hcaa2026tpasummit/

Most self-funded plans have their pharmacy rebates well in hand. The PBM captures them, reports on them, and everyone moves on. But there's a second category of manufacturer rebate value that far fewer plans are capturing: the rebates owed on specialty drugs billed under the medical benefit.

07/17/2026

67% of covered workers are in self-funded plans. The employers behind that number hold the financial risk for specialty drug costs directly.

Most aren't capturing the available offset on the medical benefit side.

PSG's 2026 data shows only 43% of employers receive medical benefit rebates vs. 93% on the pharmacy side. And nearly a third have not discussed it with their TPA or health plan.

New edition of The Rebate Report breaks down the gap and what it means for self-funded plan management. 👇

https://www.linkedin.com/posts/vativorx-llc_self-funded-employers-hold-the-financial-activity-7483971886175989760-FL3Q?utm_source=li_share&utm_content=feedcontent&utm_medium=g_dt_web&utm_campaign=copy

07/16/2026

FDA granted full approval to Tecelra® for synovial sarcoma — now expanded to patients 12+. It's the first engineered T-cell therapy approved for a solid tumor. A landmark moment for cell therapy beyond blood cancers.

https://vativorx.com/pharmacy-bulletin-07-16-2026/

On June 22, 2026, the US Food and Drug Administration (FDA) granted full approval to US WorldMeds’ Tecelra® (afamitresgene autoleucel), converting its prior accelerated approval and expanding its indication to include patients aged 12 years and older who have unresectable or metastatic synovial s...